Madison Scientific
Develops smart neuro devices to optimize hydrocephalus treatment outcomes.
Website: https://madisonscientific.com
Cover Block
PUBLIC
| Field | Value |
|---|---|
| Name | Madison Scientific |
| Tagline | Develops smart neuro devices to optimize hydrocephalus treatment outcomes |
| Headquarters | Chicago, Illinois, United States |
| Founded | 2020 |
| Stage | Seed |
| Business Model | Hardware + Software |
| Industry | Healthtech / Medical Devices |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | Seed |
| Total Disclosed | ~$10,000,000 |
Links
PUBLIC
- LinkedIn: https://www.linkedin.com/company/madison-scientific-inc
- Crunchbase: https://www.crunchbase.com/organization/madison-scientific
- PitchBook: https://pitchbook.com/profiles/company/466913-44
- Catalytic Impact Foundation portfolio page: https://www.cifimpact.org/madsci
Executive Summary
PUBLIC
Madison Scientific (also referenced in trade press as MadSci) is a Chicago-based medical device company building the SmartShunt System, an instrumented implant intended to modernize the treatment of hydrocephalus, a chronic neurological condition managed today with shunt technology that has changed relatively little in decades [BioSpace, September 2025] [Neuronewsinternational]. The company was founded in 2020 by Tyler Wanke, a serial medical device entrepreneur, and its underlying neurological science is reported to draw substantially on research conducted at the University of Wisconsin [Crain's Chicago Business]. The differentiated claim, per the company and trade coverage, is the integration of real-time intracranial pressure (ICP) monitoring with adjustable valve technology in a single implantable device, addressing a long-standing diagnostic gap in shunt failure detection [Hydrocephalus Association] [MedPath]. Wanke is concurrently associated with two other surgical device ventures (Innoblative Designs and EDGe Surgical), giving the founder a multi-company operating record in the device category [Northwestern University]. Capitalization stands at roughly $10 million in disclosed seed funding across two 2025 tranches, led on the larger tranche by WARF Ventures and joined by the Isthmus Project, Endeavor and mHub [Crunchbase, March 2025] [Crunchbase, September 2025]. Over the next 12 to 18 months, the items worth tracking are FDA regulatory pathway disclosures, first-in-human or expanded clinical data on SmartShunt, and any commercial partnership or distribution signal involving an established neurosurgical incumbent.
Data Accuracy: GREEN -- Confirmed by Crunchbase, BioSpace, and Neuronewsinternational.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | Hardware + Software (implantable device with connected diagnostics) |
| Industry / Vertical | Medical Devices, Neurosurgery |
| Technology Type | Biotech / Life Sciences |
| Geography | North America (Chicago HQ, Wisconsin research roots) |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding | ~$10M seed across two 2025 closes |
Company Overview
PUBLIC
Madison Scientific was incorporated in 2020 and operates from Chicago, Illinois, with scientific lineage tied to neurological research conducted at the University of Wisconsin [PitchBook] [Crain's Chicago Business]. The company describes itself as "a fast-growing, early-stage medical device startup" developing "smart neuro devices" for hydrocephalus management [LinkedIn]. While the corporate footprint is in Chicago, the founder's affiliation network and the WARF Ventures lead investment (the venture arm of the Wisconsin Alumni Research Foundation) reinforce the Wisconsin academic origins of the underlying technology [Crunchbase, March 2025].
The company's first publicly visible inflection came in March 2025, when it closed a $7 million seed round led by WARF Ventures to advance development of electro-mechanical solutions for patients with neurologic conditions [Crunchbase, March 2025]. A second seed tranche of $3 million followed in September 2025, bringing total disclosed seed financing to approximately $10 million and prompting trade coverage describing the round as advancing the SmartShunt program toward clinical milestones [Crunchbase, September 2025] [Neuronewsinternational]. Trade outlets, including MobiHealthNews and BioSpace, have framed the cumulative raise as a single $10 million seed package [MobiHealthNews] [BioSpace, September 2025].
Founder and CEO Tyler Wanke is a repeat medical device operator, listed publicly as co-founder of Innoblative Designs (where he is described as chief scientific officer) and as a co-founder of EDGe Surgical [Northwestern University]. He is also reported to have held advisory and investment roles at SIA [The Org] [Crunchbase]. Beyond the founder and the WARF connection, the company has not publicly disclosed a complete executive bench, although Dr. Bermans Iskandar, a pediatric neurosurgeon affiliated with the University of Wisconsin and quoted in coverage from the Isthmus Project, has spoken publicly in support of the SmartShunt approach [Isthmus Project].
Data Accuracy: GREEN -- Confirmed by Crunchbase, PitchBook, and Northwestern University.
Product and Technology
MIXED
The core product, branded the SmartShunt System, is described in third-party coverage as an implantable hydrocephalus shunt that integrates real-time intracranial pressure monitoring with adjustable valve technology, addressing the long-standing problem that conventional shunts provide no in-situ diagnostic data and frequently require imaging or surgical revision to assess whether they are functioning [Hydrocephalus Association] [MedPath] [g-medtech]. Trade coverage of the seed financing characterizes the broader thesis as developing "smart technology for neurologic conditions including hydrocephalus," with hydrocephalus as the lead indication [BioSpace, September 2025].
Hydrocephalus, the underlying condition, is caused by an accumulation of cerebrospinal fluid in the brain and is typically managed via permanent implantation of a ventricular shunt that drains fluid to another body cavity. Shunt failure rates are clinically significant, and the diagnostic ambiguity around suspected failure is precisely the gap that an instrumented shunt with telemetry and adjustable flow would address. Madison Scientific positions its system as "an integrated management solution" rather than a discrete hardware unit, suggesting a paired software or clinician-facing component, although the specifics of the data interface, cloud architecture, or clinician workflow have not been disclosed in public materials reviewed for this report [Crunchbase] [Catalytic Impact Foundation].
From a regulatory and technology-readiness standpoint, the company has not publicly disclosed an FDA submission status, IDE (Investigational Device Exemption) clearance, or first-in-human timing in any of the sources captured. The neurological science is reported to be "largely based on work of University of Wisconsin researchers" [Crain's Chicago Business], which is consistent with WARF Ventures leading the round, but the specific patent estate, exclusive license terms, and ownership of the IP are not visible in public filings reviewed here. Investors evaluating the company should treat product maturity as pre-commercial and confirm regulatory positioning directly.
Data Accuracy: YELLOW -- SmartShunt branding and functional description are corroborated across multiple trade outlets, but regulatory milestones and technical architecture are not publicly disclosed.
Market Research and Opportunity
PUBLIC
Hydrocephalus is one of the most common conditions treated by pediatric and adult neurosurgeons globally, yet shunt design has been characterized in clinical literature as an area of slow innovation, which is the structural reason a credible "smart shunt" entrant attracts attention.
The Hydrocephalus Association, a leading patient advocacy and research organization, has publicly engaged with Madison Scientific's approach and frames the integration of real-time ICP monitoring and adjustable valves as a meaningful clinical advance for patients who today cycle through emergency department visits, imaging, and revision surgeries when shunt malfunction is suspected [Hydrocephalus Association]. The competitive frame, however, is well established. The cerebrospinal fluid (CSF) shunt market is dominated by a small number of incumbents (Medtronic, Integra LifeSciences and Aesculap among them), and pricing per implant plus revision surgeries makes per-patient lifetime device economics significant.
Demand drivers worth flagging include: the clinical and economic cost of shunt revisions (a recurring cost center for pediatric neurosurgery programs), payer pressure to reduce avoidable readmissions and imaging studies, and a broader regulatory and reimbursement openness to connected implantable devices following precedents in cardiac rhythm management and neuromodulation. Adjacent and substitute markets that bear watching include endoscopic third ventriculostomy (a surgical alternative to shunting in select patients) and programmable shunt valves already on the market from incumbent vendors, which represent the closest existing analog to part of what SmartShunt proposes.
| Market signal | Value | Source |
|---|---|---|
| Disclosed seed capital into the category (this company) | ~$10M | [Crunchbase, March 2025] [Crunchbase, September 2025] |
| Lead institutional investor | WARF Ventures | [Crunchbase, March 2025] |
| Patient advocacy engagement | Hydrocephalus Association coverage of SmartShunt | [Hydrocephalus Association] |
Analyst takeaway: the publicly verifiable market signals are qualitative rather than quantitative. The combination of a translational-research investor leading the round, an engaged patient advocacy organization, and three named incumbents who have not meaningfully refreshed shunt design is a coherent setup for a focused challenger, but a buy-side reader should source an independent CSF shunt market sizing report before underwriting a TAM number.
Data Accuracy: YELLOW -- Qualitative market signals are well sourced; quantitative TAM is not publicly cited in the captured research.
Competitive Landscape
MIXED
Madison Scientific is positioned as a focused, single-indication challenger in a category dominated by diversified neurosurgical incumbents whose shunt portfolios are mature but not aggressively differentiated on connected diagnostics.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Madison Scientific | Smart, instrumented shunt for hydrocephalus | Seed, ~$10M disclosed | Integrated real-time ICP monitoring + adjustable valve in a single implant | [Crunchbase, March 2025] [Hydrocephalus Association] |
| Medtronic | Diversified medtech incumbent; programmable shunt portfolio | Public (NYSE: MDT) | Global distribution, neurosurgeon relationships, full neuro portfolio | [Crunchbase] |
| Integra LifeSciences | Neurosurgery-focused incumbent | Public (NASDAQ: IART) | Specialty neurosurgery sales force, CSF management product line | [Crunchbase] |
| Aesculap Inc. (B. Braun) | Surgical instruments and shunt systems | Subsidiary of B. Braun (private) | European footprint, programmable valve heritage | [Crunchbase] |
The competitive map breaks into three layers. The first is the entrenched shunt incumbents (Medtronic, Integra, Aesculap), each of which sells programmable valves and accessory hardware through established neurosurgery channels and benefits from physician familiarity, hospital contracting, and an installed base of revision-friendly product lines. The second is the surgical-substitute layer, principally endoscopic third ventriculostomy, which is not a device sale at all but a procedural alternative that constrains the shunt category at the margin in select pediatric patients. The third is the emerging connected-implant layer, where Madison Scientific is one of the more visible entrants and where the WARF-backed origin and a published patient-advocacy endorsement form the early credibility signals.
Where the company appears defensible today: a focused single-indication thesis with a translational-research investor lead, an academically grounded engineering approach reported to be rooted in University of Wisconsin work [Crain's Chicago Business], and a founder with two prior device companies on his record [Northwestern University]. Those are real but perishable advantages. Focus and academic provenance matter most pre-clearance; once the category moves to a commercialization phase, distribution and hospital contracting become the binding constraint, and that is precisely where the incumbents are strongest.
Where the company is most exposed: any of the three named incumbents could either acquire a connected-shunt entrant or extend an existing programmable valve with telemetry, compressing the differentiation window. Medtronic in particular has the balance sheet and the neuro distribution to fast-follow a clinically validated smart shunt, and Integra has the specialty sales force closest to the customer. Madison Scientific does not yet own a hospital channel or a published pivotal dataset, which is the gap most visible to a strategic acquirer.
The most plausible 18-month scenario: "Winner if Madison Scientific publishes credible first-in-human ICP-telemetry data and signs a strategic distribution or co-development agreement with one of the three named incumbents, converting category novelty into a defensible commercial wedge." "Loser if a programmable-valve incumbent announces a competing telemetry add-on before Madison Scientific reaches a regulatory milestone, collapsing the differentiation narrative just as the company would need to raise a Series A."
Data Accuracy: YELLOW -- Competitor identities confirmed via Crunchbase; specific competitive product roadmaps are not publicly disclosed.
Opportunity
PUBLIC
If the SmartShunt program reaches the clinic and clears regulatory review, Madison Scientific has a credible path to becoming the default connected-implant brand in hydrocephalus, a category with no current connected-device standard.
The headline opportunity. The single largest outcome here is category definition. Hydrocephalus shunting is one of the most common neurosurgical implants performed worldwide, and the clinical economics are dominated not by the initial implant but by the revision cycle (failed shunts, ambiguous failure diagnosis, repeat imaging, repeat surgery). A device that produces in-situ telemetry and supports non-invasive flow adjustment changes the unit of clinical work from "implant and hope" to "implant and manage," which is the same shift that turned cardiac rhythm management into one of the most profitable subsegments of medtech. The cited evidence that this outcome is reachable rather than aspirational: a translational-research investor lead (WARF Ventures) [Crunchbase, March 2025], engagement from the leading patient advocacy organization in the indication [Hydrocephalus Association], and a founder with two prior device companies and active academic affiliations [Northwestern University].
Growth scenarios.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Category-defining standalone | Madison Scientific clears FDA, builds a direct neurosurgery sales motion, and becomes the default smart shunt brand | Successful pivotal trial readout and FDA clearance for SmartShunt | Patient advocacy alignment and academic clinician endorsement already visible [Hydrocephalus Association] [Isthmus Project] |
| Strategic acquisition by an incumbent | Medtronic, Integra, or Aesculap acquires post-clearance to slot SmartShunt into an existing CSF-management portfolio | A clean clinical dataset plus a programmable-valve patent estate | All three named competitors already sell into this exact channel [Crunchbase] |
| Platform extension into adjacent neuro indications | The smart-implant platform extends from hydrocephalus into broader ICP-monitoring or neuromodulation use cases | Second indication clinical program funded out of a Series A | Trade coverage already frames the company as building "smart technology for neurologic conditions" beyond hydrocephalus alone [BioSpace, September 2025] |
What compounding looks like. The flywheel for an instrumented implant is data. Each implanted SmartShunt that reports ICP and flow data builds a longitudinal dataset of in-vivo shunt behavior that no incumbent currently owns, because no incumbent's shunt reports data at this resolution. That dataset, over time, supports algorithmic failure prediction, payer-grade outcomes evidence, and clinician-facing decision support, each of which raises switching costs and strengthens the case for premium pricing per implant. A second compounding axis is the regulatory one: a cleared connected implant in one neurological indication materially de-risks the same architecture in adjacent indications, which is the pattern that Inspire Medical, Axonics, and other focused neuromodulation companies followed.
The size of the win. A useful comparable is the public neuromodulation and connected-implant cohort, where focused single-indication device companies have reached multi-billion-dollar market capitalizations once they have a cleared product, a published clinical dataset, and a direct commercial team. " The path between today's seed-stage posture and that outcome is long and depends entirely on clinical readouts that have not yet been publicly disclosed.
Data Accuracy: YELLOW -- Scenarios grounded in cited investor, advocacy, and founder evidence; financial outcome ranges are explicitly framed as scenarios rather than forecasts.
Sources
PUBLIC
[Crunchbase] Madison Scientific - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/madison-scientific
[Crunchbase, March 2025] Seed Round - Madison Scientific - 2025-03-18 | https://www.crunchbase.com/funding_round/madison-scientific-seed--8c724d96
[Crunchbase, September 2025] Seed Round - Madison Scientific - 2025-09-08 | https://www.crunchbase.com/funding_round/madison-scientific-seed--c001b3ad
[Crunchbase] Tyler Wanke - Founder, CEO and Board Member @ Madison Scientific | https://www.crunchbase.com/person/tyler-wanke
[PitchBook] Madison Scientific 2026 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/466913-44
[LinkedIn] Madison Scientific Inc | https://www.linkedin.com/company/madison-scientific-inc
[The Org] Madison Scientific Inc | https://theorg.com/org/madison-scientific-inc
[Catalytic Impact Foundation] Madison Scientific | SmartShunt Innovation in Hydrocephalus Management | https://www.cifimpact.org/madsci
[Neuronewsinternational] MadSci announces US$10 million seed financing to advance SmartShunt hydrocephalus treatment | https://neuronewsinternational.com/madsci-announces-us10-million-seed-financing-to-advance-smartshunt-hydrocephalus-treatment/
[MobiHealthNews] MadSci raises $10M in seed funding for hydrocephalus system | https://www.mobihealthnews.com/news/madsci-raises-10m-seed-funding-hydrocephalus-system
[BioSpace, September 2025] Madison Scientific Closes $7M in Seed Financing | https://www.biospace.com/press-releases/madison-scientific-closes-7m-in-seed-financing
[Hydrocephalus Association] Coverage of SmartShunt approach to hydrocephalus management | https://www.hydroassoc.org/
[MedPath] SmartShunt System designed to improve hydrocephalus management | https://www.medpath.com/
[g-medtech] SmartShunt System overview | https://g-medtech.com/
[Northwestern University] Tyler Wanke profile and affiliations | https://www.northwestern.edu/
[Crain's Chicago Business] Coverage of Madison Scientific and University of Wisconsin research origins | https://www.chicagobusiness.com/
[Isthmus Project] Dr. Iskandar commentary on SmartShunt System | https://isthmusproject.com/
[PrivCo] Madison Scientific company profile | https://www.privco.com/company/madison-scientific
[Biotech Hunter] Madison Scientific company page | https://biotechhunter.com/companies/madison-scientific
Articles about Madison Scientific
- Madison Scientific Is Putting a Smart Shunt Inside the Skulls of Hydrocephalus Patients — The Chicago startup raised $10M in seed funding to modernize a brain implant that has barely changed in fifty years.